Project

Antibody targeting intracellular oncogenic Ras mutants

Project Summary

Oncogenic Ras mutants, frequently detected in human cancers, are high-priority anticancer drug targets. However, direct inhibition of oncogenic Ras mutants with small molecules has been extremely challenging. We are developing a human IgG1 format antibody

Business Model

Many patients suffer from lack of treatment because conventional drugs cannot access certain drug targets. Our vision is a world where no patient suffers from diseases with un-druggable targets. To realize this vision, we seek partnerships to further develop our cell-penetrating antibodies.

Main Achievements

- Raised $8M in Series A Financing in June 2017
- Featured as "Emerging Company" in Biocentury (Jan 2017)